

DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Inflammatory Conditions – Olumiant Drug Quantity Management Policy – Per Days

- Olumiant® (baricitinib tablets – Lilly)

REVIEW DATE: 12/19/2022

OVERVIEW

Olumiant, an inhibitor of the Janus kinases (JAK) pathways, is indicated for the following uses:¹

- **Alopecia areata**, in adults with severe disease.
- **Coronavirus Disease 2019 (COVID-19)**, for adults hospitalized requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
- **Rheumatoid arthritis**, in adults with moderate to severe active disease who have had an inadequate response to one or more tumor necrosis factor inhibitors. Olumiant is not recommended for use in combination with other JAK inhibitors, or in combination with biologics or potent immunosuppressants such as azathioprine or cyclosporine.

Dosing

Dosage recommendations for Olumiant are:¹

- **Rheumatoid arthritis:** 2 mg once daily (QD).
 - Olumiant may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
- **COVID-19:** 4 mg QD for 14 days or until hospital discharge, whichever occurs first.
- **Alopecia areata:** 2 mg QD. Increase to 4 mg QD if the response to treatment is not adequate.
 - For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg QD.
 - Once patients achieve an adequate response to treatment with 4 mg, decrease the dosage to 2 mg QD.

Availability

Olumiant is available as 1 mg, 2 mg, and 4 mg tablets in bottles of 30 tablets.¹

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Olumiant, and to manage potential premature dose escalation. Quantity limits are outlined in the table below. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity Limit	Home Delivery Maximum Quantity Limit
Olumiant® (baricitinib tablets)	1 mg tablets	30 tablets per 30 days	90 tablets per 90 days
	2 mg tablets	30 tablets per 30 days	90 tablets per 90 days
	4 mg tablets	14 tablets per 180 days	14 tablets per 180 days

CRITERIA

Olumiant 1 mg and 2 mg tablets

No overrides recommended.

Olumiant 4 mg tablets

1. If the patient is requesting Olumiant to treat alopecia areata, approve 30 tablets per 30 days at retail and 90 tablets per 90 days at home delivery.

REFERENCES

1. Olumiant® tablets [prescribing information]. Indianapolis, IN: Lilly; June 2022.